论文部分内容阅读
凝血因子Ⅶ凝血活性(FⅦc)的变化与中年男性缺血性心脏病和突发心血管病死亡的危险有关.外源途径抑制剂(EPI)是最近发现的一种组织凝血酶原FⅦ复合物抑制剂,又称外源途径抑制剂(EPI),是一种关键的止血调节剂.作者报道68例急性缺血性心脏病病人和37例正常人的FⅦ、FⅦ磷脂(FⅦ-PL)复合物和EPI活性.病人分3组:急性心肌梗死(AMI)组29例;仅有心绞痛(AP)组23例;其它心脏病(HD)组16例.均取血标本检测FⅦc活性、FⅦ酰胺溶解活性(FⅦam)和EPI活性.同时还检测FⅦ-
The change of blood coagulation factor Ⅶ coagulation activity (FⅦc) is associated with the risk of death from middle-aged male ischemic heart disease and sudden cardiovascular disease.The exogenous pathway inhibitor (EPI) is a newly discovered tissue prothrombin FⅦ complex Inhibitors, also known as exogenous pathway inhibitors (EPIs), are a key hemostatic regulator.The authors report that in 68 patients with acute ischemic heart disease and 37 normal controls, FⅦ and F Ⅶ phospholipids (FⅦ-PL) Complex and EPI activity were measured in 29 patients with acute myocardial infarction (AMI), 23 patients with angina pectoris (AP) and 16 patients with other heart disease (HD) Amidolytic activity (FⅦam) and EPI activity.FⅦ-